Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Speedy PBS win for new path

Posted 29 November 2021 AM

Health Minister Greg Hunt used the last round of PBS listing announcements for 2021 to declare AbbVie's Venclexta will be reimbursed from December 1 for Australians suffering acute myeloid leukaemia (AML).  

Venclexta will be expanded for adults with newly diagnosed AML for use in combination with azacitidine for those patients who are ineligible for intensive chemotherapy.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.